XERS News and Press, Xeris Pharmaceuticals Inc. From 04/29/21

Xeris Pharmaceuticals (XERS) announces that the United Kingdom’s Medicines and Healthcare Regulatory Agency ((MHRA)) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.The m...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the United Kingdom’s Medicines and Healt...

Penny Stock News Triggers Momentum In These Cheap Stocks When it comes to penny stocks, there are plenty of different catalysts to consider. You could look for general market trends or sector/industry-based themes. However, these are more along the line of technical catalysts. On the ot...

Xeris Pharmaceuticals (XERS) priced its registered direct offering of 6.55M shares, par value $0.0001/share to funds managed by existing investors Deerfield Management, at $4.12/share for gross proceeds of $27M.Net proceeds to be used for general corporate purposes.Offer expected to close on ...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of a registered direct offering of 6,553...

Xeris Pharmaceuticals, Inc. (XERS) Q4 2020 Earnings Conference Call March 09, 2021 08:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations Paul Edick - Chairman & Chief Executive Officer Barry Deutsch - Chief Financial Officer Conference Call Participant...

Xeris Pharmaceuticals (XERS): Q4 GAAP EPS of -$0.41 misses by $0.01.Revenue of $7.09M (+335.0% Y/Y) misses by $1.82M.Press Release For further details see: Xeris Pharmaceuticals EPS misses by $0.01, misses on revenue

Gvoke® net sales of $20.2 million for full-year 2020 Continued Gvoke prescription growth – over 350% in 2020 Strong cash position of $133.8 million Conference call and webcast today at 8:30 a.m. ET Xeris Pharmaceuticals, Inc. (Nasdaq: XERS...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its fourth quarter and...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xe...